Insulin Signaling Activates Urothelial Defenses to Reduce Urinary Tract Infection Susceptibility

胰岛素信号激活尿路上皮防御,降低尿路感染易感性

基本信息

项目摘要

Project Summary/Abstract: Diabetes mellitus is associated with many complications, including increased infection risk. With diabetes, one of the most common sites of infection is the urinary tract. In people with diabetes, urinary tract infection (UTI) is more common and has worse outcomes. The mechanisms that predispose people with diabetes to UTI are not defined. A greater appreciation for the host defense mechanisms that protect the urinary tract from microbial insult is needed to develop new UTI prevention and treatment strategies. This application’s objective is to identify how insulin signaling regulates innate immune defenses in the bladder. Our published and supporting data demonstrate that bladder urothelial defenses are regulated by insulin-mediated targets, including peroxisome proliferator-activated receptor-γ (PPARγ), insulin receptor signaling, and histone deacetylase proteins. Specifically, our data suggest PPARγ activation and histone deacetylase inhibition enhance insulin signaling, strengthen the urothelial barrier, and enhance innate immunity, including the production of antimicrobial peptides and the urothelial barrier. In contrast, silencing urothelial insulin receptor expression increases UTI susceptibility. These data support our central hypothesis that insulin and insulin receptor signaling have key roles in activating innate immune responses and regulating UTI host defense. Expanding upon these findings, we propose a comprehensive analysis of insulin’s ability to regulate bladder urothelial defense mechanisms. Aim 1 will determine the effects of progressive insulin resistance and diabetes on the bladder’s antibacterial defenses. We will also investigate if activating PPARγ triggers insulin signaling to enhance immune defenses and reduce UTI susceptibility. Aim 2 will interrogate the impact of insulin receptor signaling on the bladder’s immune defenses and urothelial responses and repair to UTI. Aim 3 will define the effect of histone deacetylase proteins on insulin signaling and the bladder’s immune defenses. Our long-term research goal is to identify why people with diabetes have increased UTI risk and improve their care. By evaluating the role of insulin signaling in host defense, our expected outcomes may have profound influence on human health as they may develop insulin-signaling targets as new UTI therapeutics.
项目摘要/摘要: 糖尿病与许多并发症有关,包括感染风险增加。患糖尿病的人, 最常见的感染部位是尿路。在糖尿病患者中,尿路感染(UTI) 更常见,结果更糟糕。糖尿病患者易患尿路感染的机制不是 已定义。更好地理解保护尿路免受微生物侵袭的宿主防御机制 开发新的尿路感染预防和治疗策略需要侮辱。此应用程序的目标是识别 胰岛素信号如何调节膀胱的先天免疫防御。我们已发布和支持的数据 证明膀胱尿路上皮防御系统受胰岛素介导的靶点调节,包括过氧化物酶 增殖物激活受体γ(PPARγ)、胰岛素受体信号转导和组蛋白脱乙酰酶蛋白。 具体地说,我们的数据表明,PPARγ激活和组蛋白脱乙酰酶抑制增强了胰岛素信号转导, 加强尿路上皮屏障,增强天然免疫力,包括产生抗菌肽 和尿路上皮屏障。相反,抑制尿路上皮胰岛素受体的表达会增加尿路感染的易感性。 这些数据支持我们的中心假设,即胰岛素和胰岛素受体信号在激活 先天免疫反应和调节UTI宿主防御。在这些发现的基础上,我们提出了 综合分析胰岛素调节膀胱尿路上皮防御机制的能力。目标1将 确定进行性胰岛素抵抗和糖尿病对膀胱抗菌防御的影响。我们 我还将研究激活PPARγ是否会触发胰岛素信号来增强免疫防御和减少尿路感染 敏感度。Aim 2将询问胰岛素受体信号对膀胱免疫防御的影响 尿路上皮对尿路感染的反应和修复。目标3将确定组蛋白脱乙酰酶蛋白对胰岛素的影响 信号和膀胱的免疫防御。我们的长期研究目标是找出为什么糖尿病患者 增加了尿路感染的风险,并改善了他们的护理。通过评估胰岛素信号在宿主防御中的作用,我们的 预期结果可能会对人类健康产生深远影响,因为它们可能会形成胰岛素信号靶标。 作为新的尿路感染疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John David Spencer其他文献

Uropathogen and host responses in pyelonephritis
肾盂肾炎中的尿路致病菌和宿主反应
  • DOI:
    10.1038/s41581-023-00737-6
  • 发表时间:
    2023-07-21
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Laura Schwartz;Juan de Dios Ruiz-Rosado;Emily Stonebrook;Brian Becknell;John David Spencer
  • 通讯作者:
    John David Spencer
Amplifying renal immunity: the role of antimicrobial peptides in pyelonephritis
增强肾脏免疫力:抗菌肽在肾盂肾炎中的作用
  • DOI:
    10.1038/nrneph.2015.105
  • 发表时间:
    2015-07-07
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Brian Becknell;Andrew Schwaderer;David S. Hains;John David Spencer
  • 通讯作者:
    John David Spencer
Current and emerging strategies to curb antibiotic-resistant urinary tract infections
当前和新兴的遏制抗生素耐药性尿路感染的策略
  • DOI:
    10.1038/s41585-024-00877-9
  • 发表时间:
    2024-05-07
  • 期刊:
  • 影响因子:
    14.600
  • 作者:
    Aaron Simoni;Laura Schwartz;Guillermo Yepes Junquera;Christina B. Ching;John David Spencer
  • 通讯作者:
    John David Spencer
Prevalence and impact of abnormal blood pressure on left ventricular hypertrophy in adolescents with congenital heart disease
先天性心脏病青少年中异常血压的患病率及其对左心室肥厚的影响
  • DOI:
    10.1016/j.ajpc.2025.101001
  • 发表时间:
    2025-06-01
  • 期刊:
  • 影响因子:
    5.900
  • 作者:
    Aaron T Walsh;Kan N Hor;Mariah Eisner;Chance Alvarado;Mahmoud Kallash;John David Spencer;Andrew H Tran
  • 通讯作者:
    Andrew H Tran
Innate immunity and urinary tract infection
  • DOI:
    10.1007/s00467-019-04269-9
  • 发表时间:
    2019-06-13
  • 期刊:
  • 影响因子:
    2.600
  • 作者:
    Christina Ching;Laura Schwartz;John David Spencer;Brian Becknell
  • 通讯作者:
    Brian Becknell

John David Spencer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John David Spencer', 18)}}的其他基金

Insulin Signaling Activates Urothelial Defenses to Reduce Urinary Tract Infection Susceptibility
胰岛素信号激活尿路上皮防御,降低尿路感染易感性
  • 批准号:
    10673963
  • 财政年份:
    2021
  • 资助金额:
    $ 55.36万
  • 项目类别:
Linking Insulin Signaling to Antimicrobial Peptide Production and the Kidney's Antibacterial Defenses
将胰岛素信号转导与抗菌肽的产生和肾脏的抗菌防御联系起来
  • 批准号:
    9883788
  • 财政年份:
    2018
  • 资助金额:
    $ 55.36万
  • 项目类别:
Linking Insulin Signaling to Antimicrobial Peptide Production and the Kidney's Antibacterial Defenses
将胰岛素信号转导与抗菌肽的产生和肾脏的抗菌防御联系起来
  • 批准号:
    10113589
  • 财政年份:
    2018
  • 资助金额:
    $ 55.36万
  • 项目类别:
The Contribution of Ribonuclease 7 to Urinary Tract Anitbacterial Defense
核糖核酸酶 7 对尿路抗菌防御的贡献
  • 批准号:
    9897601
  • 财政年份:
    2018
  • 资助金额:
    $ 55.36万
  • 项目类别:
Linking Insulin Signaling to Antimicrobial Peptide Production and the Kidney's Antibacterial Defenses
将胰岛素信号转导与抗菌肽的产生和肾脏的抗菌防御联系起来
  • 批准号:
    9523793
  • 财政年份:
    2018
  • 资助金额:
    $ 55.36万
  • 项目类别:
The Contribution of Ribonuclease 7 to Urinary Tract Anitbacterial Defense
核糖核酸酶 7 对尿路抗菌防御的贡献
  • 批准号:
    10348147
  • 财政年份:
    2018
  • 资助金额:
    $ 55.36万
  • 项目类别:
Novel Mouse Models to Assess the in vivo Significance of Ribonuclease 7 in Urinary Tract Defense
评估核糖核酸酶 7 在尿路防御中体内意义的新型小鼠模型
  • 批准号:
    9091881
  • 财政年份:
    2016
  • 资助金额:
    $ 55.36万
  • 项目类别:
Ribonuclease 7: Antimicrobial Activity in the Human Kidney and Urinary Tract
核糖核酸酶 7:人类肾脏和尿路的抗菌活性
  • 批准号:
    8461667
  • 财政年份:
    2012
  • 资助金额:
    $ 55.36万
  • 项目类别:
Ribonuclease 7: Antimicrobial Activity in the Human Kidney and Urinary Tract
核糖核酸酶 7:人类肾脏和尿路的抗菌活性
  • 批准号:
    8662257
  • 财政年份:
    2012
  • 资助金额:
    $ 55.36万
  • 项目类别:
Ribonuclease 7: Antimicrobial Activity in the Human Kidney and Urinary Tract
核糖核酸酶 7:人类肾脏和尿路的抗菌活性
  • 批准号:
    8280867
  • 财政年份:
    2012
  • 资助金额:
    $ 55.36万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 55.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 55.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 55.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了